Real-world data for patients with gestational age ≤35 weeks at birth treated with onasemnogene abeparvovec: results from the RESTORE Registry

被引：0
|
作者：
Finkel, R. [1 ]
Dabbous, O. [3 ]
Benguerba, K. [3 ]
Mumneh, N. [2 ]
Raju, D. [2 ]
Servais, L. [4 ,5 ,6 ]
机构：
[1] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[2] Novartis Gene Therapies Inc, Bannockburn, IL USA
[3] Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland
[4] Univ Oxford, Dept Paediat, MDUK Oxford Neuromuscular Ctr, Oxford, England
[5] Univ Liege, Dept Paediat, Neuromuscular Reference Ctr, Liege, Belgium
[6] Univ Hosp Liege, Liege, Belgium
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.379
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P02
引用
收藏
页码：S162 / S162
页数：1
相关论文
共 50 条
  • [1] Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
    Servais, Laurent
    Day, John W.
    De Vivo, Darryl C.
    Kirschner, Janbernd
    Mercuri, Eugenio
    Muntoni, Francesco
    Proud, Crystal M.
    Shieh, Perry B.
    Tizzano, Eduardo F.
    Quijano-Roy, Susana
    Desguerre, Isabelle
    Saito, Kayoko
    Faulkner, Eric
    Benguerba, Kamal M.
    Raju, Dheeraj
    LaMarca, Nicole
    Sun, Rui
    Anderson, Frederick A.
    Finkel, Richard S.
    JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (02) : 425 - 442
  • [2] Real-world outcomes following onasemnogene abeparvovec in patients with SMA and invasive ventilatory support: findings from the RESTORE Registry
    Servais, L.
    Shieh, P.
    Goedeker, N.
    Waldrop, M.
    Bo, R.
    Erbas, Y.
    Raju, D.
    Benguerba, K.
    Reyna, S.
    Wolff, D.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [3] Long-term safety of onasemnogene abeparvovec for patients with spinal muscular atrophy: real-world findings from the RESTORE Registry
    Servais, L.
    Alecu, I.
    Lopez-Leon, S.
    Ilic, A.
    Brueckner, A.
    Benguerba, K.
    Reyna, S.
    Dabbous, O.
    Mumneh, N.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [4] Effectiveness and Safety of Onasemnogene Abeparvovec in Older Patients with Spinal Muscular Atrophy (SMA): Real-World Outcomes from the RESTORE Registry
    Servais, Laurent
    De Vivo, Darryl
    Kirschner, Janbernd
    Mercuri, Eugenio
    Muntoni, Francesco
    Tizzano, Eduardo
    Quijano-Roy, Susana
    Saito, Kayoko
    Menier, Melissa
    LaMarca, Nicole
    Anderson, Fred
    Dabbous, Omar
    Finkel, Richard
    NEUROLOGY, 2022, 98 (18)
  • [5] Real-World outcomes following onasemnogene abeparvovec in patients with SMA and One SMN2 gene copy: findings from the RESTORE Registry
    Servais, L.
    Mathews, K.
    Bernes, S.
    Lakhotia, A.
    Tizzano, E.
    Raju, D.
    Benguerba, K.
    Reyna, S.
    Dabbous, O.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [6] Real-world data on the effectiveness and safety of onasemnogene abeparvovec in spinal muscular atrophy
    Weiss, C.
    Becker, L.
    Garbade, S.
    Johannsen, J.
    Ziegler, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [7] Real-world assessment of onasemnogene abeparvovec treatment in patients with spinal muscular atrophy: RESTORE/post-marketing surveillance in Japan
    Saito, K.
    Nagao, R.
    Tsuchida, K.
    Teshima, R.
    Kawase, K.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S92 - S93
  • [8] Characteristics of patients treated for CLL in a real-world registry: results from informCLL™
    Mato, Anthony
    Sharman, Jeff
    Pagel, John
    Brander, Danielle
    Kadish, Karen
    Tomlinson, Brian
    Ipe, David
    Yang, Huiying
    Arango-Hisijara, Israel
    Srivastava, Bhavini
    Schenkel, Brad
    Barrientos, Jacqueline
    LEUKEMIA & LYMPHOMA, 2017, 58 : 48 - 49
  • [9] Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec
    Tizzano, Eduardo F.
    Quijano-Roy, Susana
    Servais, Laurent
    Parsons, A.
    Parsons, Julie A.
    Aharoni, Sharon
    Lakhotia, Arpita
    Finkel, Richard S.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2024, 53 : 18 - 24
  • [10] REAL-WORLD EXPERIENCE OF GENE THERAPY WITH ONASEMNOGENE-ABEPARVOVEC (ZOLGENSMA®) FOR PATIENTS WITH SMA-TYPE1 IN UK
    Gowda, Vasantha
    Wraige, Elizabeth
    Ong, Min
    Atherton, Mark
    Majumdar, Anirban
    Marco, Silvia Sanchez
    Hughes, Imelda
    Mccullagh, Gary
    Muntoni, Francesco
    Jungbluth, Heinz
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
12345